Search - tctmd.com

Displaying 21 - 40 of 57

Sort: Relevancy | Date

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

News Daily News

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Michael O'Riordan

October 28, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

Yael L. Maxwell

May 15, 2020

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

Todd Neale

August 13, 2018

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Daily News

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Michael O'Riordan

January 19, 2018

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

Presentation VIVA 2017

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

Presenter: Ehrin J. Armstrong

September 19, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

Advertisement

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

P2Y12 Inhibitor Monotherapy Edges Out Aspirin for Secondary Prevention

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Quality of CAD Care Varies by Type of Medicare Coverage

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

High Rate of Clinical Events at 6 Months for Ischemic CVD Patients

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Is Aspirin Really a Class I Medication in Peripheral Artery Disease?

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content